Singapore's Aslan Pharma raises $42m in US IPO
Aslan Pharmaceutical, a Singapore-based drug developer that focuses on cancer treatments, has raised $42.2 million in its US IPO. The VC-backed company listed on the Taiwan Stock Exchange last June.
Aslan sold 6 million American Depository Shares (ADS) – having initially planned to offload 7.5 million – at $7.03 apiece, according to a filing. None of the company’s existing investors made a partial...
More on Southeast Asia
Latest News
Asian GPs slow implementation of ESG policies - survey
Asia-based private equity firms are assigning more dedicated resources to environment, social, and governance (ESG) programmes, but policy changes have slowed in the past 12 months, in part due to concerns raised internally and by LPs, according to a...
Singapore fintech start-up LXA gets $10m seed round
New Enterprise Associates (NEA) has led a USD 10m seed round for Singapore’s LXA, a financial technology start-up launched by a former Asia senior executive at The Blackstone Group.
India's InCred announces $60m round, claims unicorn status
Indian non-bank lender InCred Financial Services said it has received INR 5bn (USD 60m) at a valuation of at least USD 1bn from unnamed investors including “a global private equity fund.”
Insight leads $50m round for Australia's Roller
Insight Partners has led a USD 50m round for Australia’s Roller, a venue management software provider specializing in family fun parks.